Perfluorocarbon (PFC) Inhalation Treatment of Acute Lung Injury/Acute Respiratory Distress Syndrome
The Randomized Controlled Trial (RCT) on the Vaporized Perfluorocarbon (PFC) Inhalation Treatment of Acute Respiratory Distress Syndrome With the Invasive Mechanical Ventilation(IMV)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: zhixin Liang, M.D.
- Phone Number: 86-10-13651205567
- Email: 13651205567@163.com
Study Contact Backup
- Name: Chen Yang, M.D.
- Phone Number: 86-10-18618333365
- Email: ycmarcia@hotmail.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100853
- Recruiting
- Chinese PLA General Hospital
-
Beijing, Beijing, China, 100000
- Recruiting
- 306 Hospital of PLA
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age: 18-75 years old
- Some clear risk aetiological agents of acute respiratory distress syndrome
- Acute onset, with corresponding clinical manifestations
- PaO2/FiO2 ≤ 300mmHg
- Chest radiograph or chest computerized tomography prompting bilateral pulmonary infiltrate shadow
- pulmonary capillary wedge pressure (PCWP) ≤ 18 mmHg or clinical cardiogenic pulmonary edema can be excluded
- respiratory rate (RR) ≥ 30bpm and (or) respiratory distress
- requiring tracheal intubation or tracheostomy for invasive mechanical ventilation
- or have received invasive mechanical ventilation time ≤ 3 days
Exclusion Criteria:
- Age: < 18 years old or > 75 years old
- During the early stage of the treatment, the use of mechanical ventilation for more than 3 days other than ALI/ARDS for reasons
- Lung parenchyma and airway surgery carried out within 30 days of the screening period
- Severe arrhythmia and myocardial ischemia after cardiopulmonary resuscitation
- Systolic blood pressure < 90 mm Hg, and can not maintain its stability with intravenous infusion and vasopressor drugs
- Intubation due to interstitial lung disease (E.g., sarcoidosis, idiopathic pulmonary fibrosis)
- Any active pneumothorax or mediastinal emphysema
- Risk factors leading to the death within 3 months in addition to ALI/ARDS during the screening period (E.g., end-stage cancer)
- Of perfluorocarbons' allergies
- Pregnant, breastfeeding women
- Attending other clinical trial within 30 days of the screening period
- Severe organ dysfunction (Marshall score ≥ 3 or Sequential Organ Failure Assessment(SOFA) score≥ 3, including serious liver and kidney dysfunction, upper gastrointestinal hemorrhage, etc.)
- Acute Physiology and Chronic Health Evaluation(APACHE) II score ≥ 30, high risk of death
- The researchers consider other situations not suitable for the case to participate in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: SINGLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Perfluorocarbon
|
Vaporized PFC Inhalation 100ml/8h for 5 days
|
|
Placebo Comparator: Sterile Water for Injection
|
Inhalation of Sterile Water for Injection, 100ml/8h for 5 days
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
oxygenation index, respiratory mechanics
Time Frame: three years
|
oxygenation index and respiratory mechanics will be abtained before and 1, 2, 4h after every inhalation,
|
three years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Survival
Time Frame: three years
|
ventilator-free days, 28-day mortality
|
three years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: Liangan Chen, M.D. PHD., Chinese PLA General Hospital
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PLAGH-PFC
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.